Search

everythinglearnresearchcommunity

for

Search:↓

The French Endocrine Society suggests diagnosing PCOS with two of three signs, recommends lifestyle changes and clomiphene for treatment, and calls for more research on certain treatments and tests.

The mineralocorticoid receptor may play a role in skin and hair health and could be a new target for treating related disorders.

Systemic glucocorticosteroids are a primary treatment for various skin conditions but require careful management due to potential side effects and relapses.

Minoxidil helps some bald men, but most lose hair again when stopping.

Some people experience severe, long-lasting side effects from fluoroquinolone antibiotics, leading to the recommendation of limited use and increased awareness of these risks.

Cyclophosphamide has serious side effects, but long-term follow-up can help manage risks.

Insulin-lowering medications show promise for PCOS symptoms but can't be the main treatment yet due to limited long-term research.

Scalp cooling is largely ineffective in preventing hair loss from breast cancer chemotherapy.

Some plant-derived compounds may help with hormonal conditions, but more research is needed to confirm their effectiveness.

Menopause-related hormonal changes affect hair but are not the only cause of hair changes in middle-aged women.

The document suggests that clinical trials for PCOS should focus on meaningful primary outcomes like live birth rates, rather than less reliable surrogate markers.

Bariatric surgery may help severely obese teenagers but has risks and requires careful patient selection and long-term care.

Early diagnosis and treatment are crucial for preventing permanent hair loss in various scalp conditions, and while new treatments are promising, more research is needed to evaluate their effectiveness.

Losing eyelashes or eyebrows can be a sign of many different health problems and needs a careful approach to treat effectively.

Food deprivation increases MST enzyme in the brain, possibly affecting energy balance.

5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.

Early diagnosis and treatment of TPP can prevent complications.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

Minoxidil may cause heart issues in animals and humans.

More PDCD4 is linked to obesity, insulin problems, and cell death in ovaries for those with polycystic ovary syndrome.

Hair loss linked to metabolic issues and insulin resistance; early assessment may reduce future health risks.

Menstrual disorders are common in adolescents and can be influenced by weight, activity, and health issues, requiring careful evaluation and more research for effective treatment.

5α reductase inhibitors treat hair loss but may cause sexual side effects and risks.

Premature ovarian insufficiency (POI) can harm women's sexual health, and they may benefit from hormone therapy and counseling.

Insulin-sensitizing drugs like metformin can help with ovulation, weight loss, and lower testosterone in some women with PCOS.

Dutasteride makes alcohol less sedating and may lead to less drinking in men.

Low testosterone and 5α-reductase inhibitors can harm men's metabolic and sexual health; testosterone therapy may help, but discussing 5α-RIs' side effects is important.

Hormonal treatments are effective as a second-line option for moderate-to-severe acne in females, but should be used with caution due to health risks.

Woodhouse-Sakati syndrome often causes sexual development issues, hair loss, learning disabilities, deafness, muscle contractions, limb pain, and diabetes.

5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.